Related Experiment Video
Updated: Jun 16, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Postoperative Results After Patient Blood Management with Intravenous Iron Treatment Implementation for Preoperative
Ana Centeno1, Carlos Jerico2, Lana Bijelic3
1Colorectal Surgery Unit, General Surgery Department, Complex Hospitalari Moisès Broggi-Consorci Sanitari Integral, 08970 Sant Joan Despí, Spain.
Insights
Intravenous iron effectively corrects preoperative anemia in colorectal cancer patients, reducing the need for blood transfusions and improving surgical outcomes within patient blood management programs.
Area of Science:
- Oncology
- Hematology
- Surgical Outcomes
Background:
- Preoperative anemia (PA) is common in colorectal cancer (CRC) patients, negatively impacting surgical results.
- Patient Blood Management (PBM) systems aim to optimize blood product use and treat PA with intravenous iron (IVI).
- IVI may enhance postoperative outcomes and decrease the requirement for red blood cell (RBC) transfusions.
Purpose of the Study:
- To assess the efficacy of IVI within a PBM pathway for CRC patients with PA.
- To evaluate surgical outcomes and the incidence of postoperative red blood cell transfusion (RBCT) after IVI treatment.
Main Methods:
- A cohort study of CRC patients (2012-2018) was conducted.
- Patients were grouped by hemoglobin levels: non-anemic (Group 1), mildly anemic (Group 2), and IVI-treated anemic (Group 3).
- Hb changes, surgical complications (Clavien-Dindo), 30-day mortality, and RBCT rates were compared across groups.
Main Results:
- Group 3 showed a mean Hb increase of 1.2 mg/dL after IVI, sustained until discharge.
- No significant differences in Clavien-Dindo III-IV complications or 30-day mortality were observed among groups.
- The RBCT rate in Group 3 (21.6%) was significantly lower than in patients receiving preoperative RBCT (32.6%).
Conclusions:
- IVI is a safe and effective method for rapid PA correction in CRC patients.
- Implementing IVI within PBM pathways can potentially lower postoperative RBCT rates.
Abstract:
Background: PA is frequent in CRC patients and known to be detrimental to surgical outcomes. PBM systems promote rational use of blood products and PA treatment with IVI, which could potentially improve postoperative results and the need for RBCT. Objective: To evaluate the effectiveness of Intravenous Iron (IVI) within a Patient Blood Management (PBM) pathway in Colorectal Cancer (CRC) patients with Preoperative Anemia (PA). To analyze surgical results after treatment and the need for Red Blood Cell Transfusion (RBCT) after surgery. Methods: Cohort study of CRC patients between 2012 and 2018, divided into groups: non-anemic patients (Hemoglobin Hb > 13 g/dL, Group 1), mildly anemic patients (Hb 12-13 mg/dL, Group 2), and patients treated with IVI (Hb < 12 mg/dL or Hb 12-13 mg/dL with risk factors, Group 3). Effectiveness of IVI treatment measured based on differences in Hb changes. Surgical complications were assessed and compared among groups, as well as the RBCT rate. The latter was also compared between Group 3 patients and those receiving preoperative RBCT. Results: Group 3 presented with a baseline Hb of 9.9 (±1.5) mg/dL with an increase of 1.2 (±1.9) mg/dL after treatment, which endured until discharge. Clavien-Dindo III-IV complications were 6.5%, and 30-day Mortality was 1.4% in all the series, without differences among Groups. RBCT rate in Group 3 patients was 21.6%, significantly lower than that of patients receiving preoperative RBCT (32.6%). Conclusions: IVI is a safe and effective measure for a fast PA correction in CCR patients and could potentially reduce postoperative RBCT rates.
More Related Videos
07:59Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
05:22Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026